Nefazodone in the Treatment of Social Phobia
Information source: Emory University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Social Anxiety Disorder (SAD)
Intervention: Nefazodone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Emory University Official(s) and/or principal investigator(s):
Charles B Nemeroff, MD, PhD, Principal Investigator, Affiliation: Emory University Department of Psychiatry and Behavioral Sciences
Clinton D Kilts, PhD, Study Director, Affiliation: Emory University Department of Psychiatry and Behavioral Sciences
Jeffrey Newport, MD, Study Director, Affiliation: Emory University Department of Psychiatry and Behavioral Sciences
Summary
The purpose of this study is to determine the effectiveness of nefazadone in patients with
social anxiety disorder (SAD).
Clinical Details
Official title: Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates
Study design: Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Efficacy Study
Detailed description:
The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist
nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when
confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes
in cerebral blood flow were correlated with self-rated anxiety measures.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- DSM-IV diagnosis of generalized social anxiety disorder, males and females between the
ages of 18-65
Exclusion Criteria:
- A history of bipolar disorder, psychotic illness, or any other anxiety disorders,
organic brain disease or active drug or alcohol abuse within one year as assessed by
the SCID-P and interview, or a concurrent medical condition that would not be
compatible with the study in the opinion of the principal investigator. Patients
required to be free of psychotropic or beta-blocker medication for 2 weeks prior to
study. Pts taking fluoxetine required to be drug-free for 6 weeks.
Locations and Contacts
Emory University Depatment of Psychiatry and Behavioral Sciences, Atlanta, Georgia 30322, United States
Additional Information
Last updated: October 3, 2005
|
